NEW YORK (GenomeWeb News) – Trovagene today said that it has entered into an R&D agreement with PerkinElmer Health Sciences to design an assay for evaluating a patient's risk of developing hepatocellular carcinoma.

The assay will be based on Trovagene's TrNA technology, the company said in a document filed with the US Securities and Exchange Commission, adding that both firms will jointly validate the assay and evaluate the possibility of combining the TrNA technology with PerkinElmer's technology for automation of nucleic acid isolation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

Wired reports that 23andMe is trying to bolster its outside collaborations.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.